- Home
- RC vs RLMD Comparison
RC vs RLMD Comparison
Compare RC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | RLMD |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | 475 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.9M | 319.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | RC | RLMD |
|---|---|---|
| Price | $1.52 | $6.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.81 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 2.7M | 1.7M |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $67.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $1.50 | $0.24 |
| 52 Week High | $5.24 | $7.41 |
Technical Indicators
Market Signals| Indicator | RC | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 60.00 |
| Support Level | N/A | $3.65 |
| Resistance Level | $2.15 | $7.41 |
| Average True Range (ATR) | 0.08 | 0.46 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.30 | 53.40 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.